Kostas Kaloulis

Kostas holds a PhD in Molecular Embryology from the University of Geneva and did post-doctoral research in cancer genetics at the Swiss Institute of Cancer Research. Kostas is a Venture Partner at the +ND Capital since 2018. He is serving as the CEO for EVIR Therapeutics; the company is based on a highly innovative project from EPFL, which Kostas helped structuring and spinning out. He is also CEO for Arctos Medical, which he structured and span out from the University of Bern. In parallel, he is the co-founder and Board member of Avrion Therapeutics, another company he structured and span out from EPFL. Prior to this, Kostas structured and headed the Innovation fund (catalyze4lfe) for the Life Sciences school at EPFL, and on behalf of InnoSuisse (the Swiss Federal Innovation Initiative) he acted as an expert for new healthcare startups and technologies across Switzerland. Kostas has more than 20 years of experience in research, Technology Transfer, serial entrepreneurship, and biopharmaceutical business development & strategic innovation (Merck KGaA). Over the years, he has devised, negotiated, and managed numerous research and licensing deals and strategic multiple-party partnerships (public and/or private) with the goal to help building innovative therapeutics pipelines. His main career motivation is to bring scientific breakthroughs to patients. As co-founder of the ReMedys Foundation, he volunteers to support the development of products/projects, independent of their commercial interest, if they carry great potential impact to patients’ lives.